Search

… dystrophic epidermolysis bullosa (DEB) An update on the innovation/discovery pipeline including programs for Usher …

… oligonucleotides for severe genetic diseases through our innovation unit.” Financial Highlights At June 30, 2016, … preclinical development of QR-110 and progress of our innovation programs such as QR-313 for epidermolysis bullosa, …

… focuses on identifying transformational and disruptive innovations across the biopharmaceutical and medical … and commercialization activities. Gerard Platenburg, Chief Innovation Officer at ProQR, will join Yarrow’s board of … focuses on identifying transformational and disruptive innovations across the biopharmaceutical and medical …

… during the Foundation Fighting Blindness/Casey Innovation summit prior to ARVO. LEIDEN, the Netherlands, … Ophthalmology Franchise of ProQR Session:   FFB/Casey Innovation summit prior to ARVO: Retinal Cell and Gene …

… to help patients with CF, LCA 10 and DEB, we continue to innovate in RNA science. This innovation effort has led to the discovery of a novel RNA …

… We have also made a lot of progress in advancing our innovation pipeline", said Daniel de Boer, Chief Executive … from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 633545. About …

… progress in all of our programs as well as in our innovation efforts. Our QR-010 program for CF has completed … from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 633545. About …